Syneron Medical Announces Syneron Beauty's Successful Launch of the me smooth and the Pearl Brilliant White Systems More than 10,000 me smooth ELOS based hair removal units and 17,000 Pearl brilliant ionic teeth whitening units sold in 24 hours in launch event on QVC®
YOKNEAM, Israel, May 2, 2013 /PRNewswire/ -- Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announced today the successful launch of Syneron Beauty's me smooth At-Home Professional Hair Removal System and the Pearl Brilliant White Ionic Teeth Whitening System on QVC®. Syneron Beauty sold in the 24 hour launch event more than 10,000 and 17,000 units of the me smooth and Pearl Brilliant White systems, respectively*.
Fabian Tenenbaum, Chief Executive Officer of Syneron Beauty, said "We are very pleased with this initial launch of our products, which corresponded with the North American release of the latest versions of our popular me at-home hair removal system and Pearl teeth whitening system. We benefitted from the opportunity to educate consumers on the innovative technologies behind our products, including the elos technology in the me hair-removal system, which is based on the leading professional products sold by Syneron Medical. We look forward to further leveraging our strong brand and technology as the launch continues."
The me smooth will be available at prestige beauty retailers including Nordstrom, Neiman Marcus, Bloomingdales, Ulta, Sephora and Space NK as well as on QVC and mePower.com. The Pearl Ionic Teeth Whitening Systems, Brilliant White and Gentle White, are available at prestige beauty retailers including Nordstrom, Neiman Marcus, Bloomingdales and Ulta, as well as on IonicPearl.com.
Dr. Shimon Eckhouse, Chief Executive Officer of Syneron Medical, said, "The launch of the me smooth system in U.S. is a significant milestone, marking the first elos-based home-use product sold in this market. We are very pleased with the successful initial launch, which also includes the prestige beauty retail sales channel. Combined with the early success of the new Pearl Brilliant White system, we remain on track to reach breakeven performance in Syneron Beauty in 2013."
About Syneron Beauty
Syneron Beauty is a pioneer in the design, development and distribution of energy-based consumer aesthetic products. The Company's products are based on clinically proven technologies derived from the professional medical aesthetic device market, enabling patients to achieve professional-like results in an at-home setting. Syneron Beauty currently markets the me™ brand of home-use hair removal systems (www.mePower.com), the Pearl™ family of teeth whitening products and the Tanda™ family of home-use light therapy products. Syneron Beauty is based in New York and is a wholly owned subsidiary of Syneron Medical Ltd. (ELOS).
About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that Syneron Beauty may not meet its performance goals for 2013, as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.